Zacks Research Estimates Maximus’ FY2026 Earnings (NYSE:MMS)

Maximus, Inc. (NYSE:MMS) – Investment analysts at Zacks Research reduced their FY2026 EPS estimates for Maximus in a research report issued to clients and investors on Wednesday, August 26th. Zacks Research analyst Team now anticipates that the health services provider will earn $8.07 per share for the year, down from their previous estimate of $8.41. Zacks Research has a “Strong Sell” rating on the stock. The consensus estimate for Maximus’ current full-year earnings is $8.01 per share. Zacks Research also issued estimates for Maximus’ Q1 2027 earnings at $1.93 EPS, Q2 2027 earnings at $2.25 EPS, Q3 2027 earnings at $2.27 EPS, Q4 2027 earnings at $1.92 EPS, FY2027 earnings at $8.37 EPS, Q1 2028 earnings at $2.09 EPS, Q2 2028 earnings at $2.31 EPS, Q3 2028 earnings at $2.56 EPS and FY2028 earnings at $9.15 EPS.

Maximus (NYSE:MMS) last announced its quarterly earnings results on Thursday, August 6th. The health services provider reported $2.22 EPS for the quarter, beating analysts’ consensus estimates of $2.21 by $0.01. The firm had revenue of $1.28 billion during the quarter, compared to analysts’ expectations of $1.33 billion. Maximus had a net margin of 7.07% and a return on equity of 24.91%. The company’s revenue for the quarter was down 5.1% compared to the same quarter last year. During the same quarter last year, the company posted $2.16 earnings per share. Maximus has set its FY 2026 guidance at 7.900-8.200 EPS.

A number of other equities analysts also recently weighed in on the company. Weiss Ratings reissued a “hold (c-)” rating on shares of Maximus in a research report on Monday, August 17th. Wall Street Zen cut Maximus from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Maximus has an average rating of “Reduce”.

Maximus Stock Up 0.6%

Shares of MMS stock opened at $58.88 on Thursday. Maximus has a 52-week low of $52.73 and a 52-week high of $100.00. The stock has a market cap of $3.08 billion, a price-to-earnings ratio of 8.70 and a beta of 0.59. The firm’s 50-day moving average is $57.50 and its 200-day moving average is $63.77. The company has a debt-to-equity ratio of 0.90, a quick ratio of 2.42 and a current ratio of 2.42.

Maximus Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, August 31st. Stockholders of record on Friday, August 14th will be issued a dividend of $0.33 per share. This represents a $1.32 dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date is Friday, August 14th. Maximus’s payout ratio is currently 19.50%.

Hedge Funds Weigh In On Maximus

Several institutional investors and hedge funds have recently made changes to their positions in MMS. Farther Finance Advisors LLC grew its holdings in Maximus by 69.0% in the 4th quarter. Farther Finance Advisors LLC now owns 284 shares of the health services provider’s stock valued at $25,000 after buying an additional 116 shares in the last quarter. Advisory Services Network LLC acquired a new stake in shares of Maximus during the third quarter worth $32,000. Northwestern Mutual Wealth Management Co. boosted its position in shares of Maximus by 225.2% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 439 shares of the health services provider’s stock valued at $38,000 after acquiring an additional 304 shares during the period. Canada Pension Plan Investment Board bought a new stake in shares of Maximus in the second quarter valued at about $35,000. Finally, Danske Bank A S acquired a new position in shares of Maximus in the third quarter valued at about $55,000. Institutional investors and hedge funds own 97.21% of the company’s stock.

Maximus News Summary

Here are the key news stories impacting Maximus this week:

• Positive Sentiment: Zacks raised its FY2028 EPS forecast to $9.15 from $8.94. The firm also increased estimates for Q1 2028 to $2.09 from $2.02, Q2 2028 to $2.31 from $2.22, and Q3 2028 to $2.56 from $2.41, suggesting improved expectations for Maximus’s longer-term earnings potential.
• Positive Sentiment: Zacks’s FY2026 EPS estimate of $8.07 remains slightly above the broader consensus forecast of $8.01, which may offer some reassurance despite the downward revision.
• Neutral Sentiment: The analyst expects Maximus to earn $8.37 per share in FY2027, with quarterly estimates of $1.93, $2.25, $2.27 and $1.92. The overall FY2027 forecast was only modestly reduced from $8.43, indicating limited change to the medium-term outlook.
• Negative Sentiment: Zacks cut its FY2026 EPS estimate from $8.41 to $8.07, reduced FY2027’s fourth-quarter forecast from $1.95 to $1.92, and lowered Q1 2027 EPS to $1.93 from $1.94 and Q3 2027 EPS to $2.27 from $2.33. These revisions signal softer near-term expectations.
• Negative Sentiment: Zacks continues to rate MMS “Strong Sell,” which could weigh on investor sentiment even though the stock trades at a relatively low P/E ratio and the firm raised its longer-term forecasts.

Maximus Company Profile

Maximus, Inc (NYSE: MMS) is a global provider of government services focused on delivering health and human services programs. The company partners with federal, state, and local agencies to administer and manage programs that support individuals and families across various stages of life. Key service areas include eligibility determination and enrollment services for Medicaid, Medicare, Children’s Health Insurance Program (CHIP) and other public assistance programs, as well as call center operations, case management and program integrity solutions.